Investor Presentation
Roquefort Therapeutics plc announced that following shareholder approval of the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc. and the subsequent name change to Coiled Therapeutics plc, effective March 27, 2026, the leadership team will host a live investor presentation on Monday, March 30, 2026, at 2:00 PM BST. The presentation will cover the acquisition and name change, and investors are encouraged to pre-submit questions.
Select text to share a quote on X · sign in to keep highlights & notes in your COIL notes
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that following the General Meeting held earlier today at which shareholders approved the acquisition of the exclusive worldwide licence of AO-252 from Coiled Therapeutics, Inc. and the name change to Coiled Therapeutics plc, effective 27 March 2026, the leadership team will host a live interactive presentation on the Engage Investor platform, on Monday 30 March 2026, at 2:00pm BST.
Dr Sotirios Stergiopoulos, Chairman Coiled Therapeutics and Sridhar Vempati, CEO Coiled Therapeutics (together with Stephen West, current Chairman of Roquefort Therapeutics) will present.
The Company welcomes all current shareholders and interested investors to join, and encourages investors to pre-submit questions. Investors can also submit questions at any time during the live presentation.
Investors can sign up to Engage Investor at no cost and follow the Company from their personalised investor hub, and can register interest in this event here:
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.